Initial 24-hours Levodopa Carbidopa Intestinal Gel initiation in advanced Parkinson’s disease
Objective: To evaluate the profile of those patients with advanced Parkinson’s Disease (APD) in which we decided to use continuous 24-hour administration of Levodopa Carbidopa…The impact of wearing ‘OFF’ (WO) episodes on non-motor symptoms (NMS) burden and quality of life (QoL) in Parkinson’s disease (PD) patients
Objective: To estimate the frequency and severity of NMS and their impact on QoL among patients with moderate to advanced PD with WO episodes versus…Fecal tyrosine decarboxylase and motor response complications in Parkinson’s Disease
Objective: To investigate the clinical correlates of gut microbe-derived tyrosine decarboxylase (tdc) and motor dysfunction in Parkinson’s Disease (PD) patients. Background: Gut microbe-derived tdc was…On-demand therapy (ODT) in Parkinson’s disease: a survey of advanced practice providers
Objective: A survey of neurology Advanced Practice Providers (APPs) provides insights into their perspectives on managing and treating patients with Parkinson’s disease (PD) in the…Motor complications in Parkinson’s disease
Objective: To determine the presence, severity, functional impact and predisposing factors of motor complications. Background: Motor complications are well recognized in Parkinson’s disease (PD), but…Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study – results of the Belgian subgroup
Objective: The primary objective of the study was to evaluate the proportion of Parkinson’s Disease (PD) patients in Movement Disorder Centers with Advanced Parkinson’s Disease…Continuous estimation of Parkinson’s on-off states using wearable devices
Objective: Utilize passive, continuous data from mobile and wearable devices to estimate on-off states in Parkinson’s patients. Background: The Hauser motor diary is often used…Defining neuropsychiatric symptoms fluctuations in Parkinson’s disease
Objective: To evaluate the demographic and clinical correlates of Parkinson’s disease (PD) patients with fluctuations of neuropsychiatric symptoms (NPS-F). Background: Clinical correlates of fluctuations of…Psychometric properties of the Neuropsychiatric Fluctuations Scale: preliminary results in patients with Parkinson’s disease
Objective: To assess the psychometric properties of the Neuropsychiatric Fluctuations Scale (NFS) [1] in patients with Parkinson’s disease (PD) Background: PD presents with non-motor symptoms…Utilization pattern and factors associated with amantadine use in Parkinson’s disease (PD) of the French NS-Park cohort
Objective: To assess amantadine use in the French NS-Park cohort and factors associated with its prescription Background: Amantadine, a unique dopamine/glutamate drug, is approved worldwide…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 26
- Next Page »